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REVIEWContemporary resistance trends and mechanisms for the old antibiotics
colistin, temocillin, fosfomycin, mecillinam and nitrofurantoinC. G. Giske1,2
1) Department of Clinical Microbiology, Karolinska University Hospital and 2) Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska
Institutet, Stockholm, SwedenAbstractRecently there has been a renewed interest in reviving older antimicrobial agents, particularly those with activity against multidrug-resistant
Gram-negative bacilli. Because many such antimicrobials are not licensed in all countries, there is a paucity of international surveillance data,
and none of these agents is part of any antimicrobial resistance surveillance on the level of the EU. Some of the agents are used in lower
urinary tract infection, whereas most available supranational surveillance data pertain to severe infections such as bloodstream infections.
Among old antimicrobial agents, the most interesting compounds from a clinical perspective are the two intravenous agents colistin and
temocillin, the two oral agents pivmecillinam and nitrofurantoin, and fosfomycin, which is available both for intravenous and oral use. The
most interesting target microorganisms are Enterobacteriaceae, although colistin also has good activity against Pseudomonas aeruginosa and
Acinetobacter species. Recent European surveillance data point to approximately 5% resistance to colistin in general among Klebsiella
pneumoniae, whereas resistance in carbapenemase-producing Enterobacteriaceae may be up to 15% to 20% in some settings. Temocillin is
stable against many extended-spectrum β-lactamase–producing Enterobacteriaceae and some carbapenemase producers, but low-level
resistance is not uncommon in extended-spectrum β-lactamase producers, and high-level resistance is always seen with OXA-48 group
carbapenemases. Fosfomycin resistance is rare in areas with limited use but increasing is in countries with higher usage. Resistance levels to
mecillinam and nitrofurantoin are generally low in EU countries, but clinical data supporting treatment efﬁcacy of multidrug-resistant strains
are few. Systematic surveillance of the above-mentioned agents will be important, particularly for those agents used in severe infections.
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E-mail: christian.giske@karolinska.seIntroductionThe combination of a lack of novel antimicrobials entering
clinical practice and the increasing antimicrobial resistance in
Gram-negative bacilli has led to renewed interest in reviving
older agents currently available in one or several EU countries.
Because these antimicrobials are not licensed in all countries,Clinical Microbiology and Infection © 2015 European Society of Cthere is a paucity of international surveillance data, and none of
these agents is part of any antimicrobial resistance surveillance
at the EU level. Some of the agents are also used in lower
urinary tract infection (UTI), whereas most available suprana-
tional surveillance data pertain to severe infections such as
bloodstream infections.
Among old antimicrobial agents, the most interesting com-
pounds from a clinical perspective are the two intravenous
agents colistin and temocillin, the two oral agents pivmecillinam
and nitrofurantoin, and fosfomycin, which is available both for
intravenous and oral use. The most interesting target microor-
ganisms are Enterobacteriaceae, although colistin also has good
activity against Pseudomonas aeruginosa and Acinetobacter species.
The agents are clinically interesting for various reasons. Colistin
is important mainly as a last resort agent for treatment ofClin Microbiol Infect 2015; 21: 899–905
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
http://dx.doi.org/10.1016/j.cmi.2015.05.022
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bacilli. Temocillin is interesting as a carbapenem-sparing agent
with limited ecologic impact. Pivmecillinam, nitrofurantoin and
fosfomycin are mostly interesting from the perspective of
treating lower UTIs.
Here I review mechanisms of action and resistance for the
different agents, and I present available supranational surveil-
lance data. I also identify areas where improvement of sur-
veillance is necessary.ColistinTABLE 1. Colistin resistance in Enterobacteriaceae
(n [ 8341) and Pseudomonas aeruginosa (n [ 2191) in study
of 31 medical centres, 2011–2012
Species/categorya Colistin resistance (EUCAST) (%)
P. aeruginosa (n = 2191) 0.2
MDR P. aeruginosa (n = 698) 0.6
Escherichia coli (n = 3843) 0.5
E. coli with ESBL (n = 715) 0.6
Klebsiella pneumoniae (n = 1408) 5.4
K. pneumoniae with ESBL (n = 633) 9.7
Klebsiella oxytoca (n = 304) 0.7
Enterobacter spp. (n = 899) 10.9
Citrobacter spp. (n = 389) 0.3
Data from Sader et al. [7].
EUCAST, European Committee on Antimicrobial Susceptibility Testing; ESBL,
extended-spectrum β-lactamase; MDR, multidrug resistant.
aSpecies with natural resistance to colistin (Proteae, Serratia) are not included.Colistin and other polymyxins are cationic antimicrobial pep-
tides interfering with the negatively charged outer membrane of
Gram-negative bacteria. The binding of polymyxins leads to
disruption of the membrane and thereby promotes killing of
bacteria [1]. Resistance normally occurs through mutations in
the two-component regulatory system PhoPQ-PmrAB, which
leads to an altered charge in the lipopolysaccharide (LPS) and
therefore lower binding of the positively charged polymyxins
[2]. The two-component regulatory system and its relation to
transcription of the arn complex is outlined in Fig. 1, which also
shows the two most common sites of mutation. Increased
transcription in the arn complex leads to biosynthesis of the
cationic 4-amino-4-deoxy-l-arabinose (LAra4N), which when
inserted in the LPS lowers the afﬁnity of the positively charged
polymyxins [2]. Recent reports indicate that mutations in MgrB,
the negative regulator of PhoQ, as well as in the membrane-
bound kinase PmrB are the two most important mechanisms
of resistance in clinical isolates. The evidence to suggest that
these mechanisms are most important comprise ﬁndings of
these mutations in clinical isolates [3,4], as well as experimental
evidence with insertional inactivation of MgrB [5] and transfer
of plasmids encoding mutated variants of PmrB [6].Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectLarger surveillance studies have been carried out to a limited
degree, but a recently published study comprising isolates from
2011–2012 from 31 medical centres in 13 European countries
plus Turkey and Israel demonstrated concerning resistance
levels in Klebsiella pneumoniae, whereas resistance in
P. aeruginosa and Escherichia coli both were low (Table 1) [7].
The strength of this report is that all strains were tested in a
central laboratory with reference-standard methodology for
susceptibility testing. In the EARS-Net report from 2013, only
26.4% of all K. pneumoniae isolates had antimicrobial suscepti-
bility testing (AST) results for polymyxins [8]. Not all countries
reported data, and for some countries, data on only very few
isolates were available. Overall, 8.8% of the K. pneumoniae
isolates were resistant to polymyxins, and a majority of the
isolates were from Greece, Italy, Romania and Hungary.
Worryingly, 32% of carbapenem-resistant isolates were resis-
tant to polymyxins. For Acinetobacter spp., 17 countries re-
ported polymyxin AST data in the EARS-Net 2013 report.
Among 2217 isolates (52% of the reported isolates), 5% of the
isolates were resistant to polymyxins. More than 80% of the
resistant isolates were reported from Greece and Italy. TheFIG. 1. Two-component regulatory
system for modiﬁcation of charge in
LPS of Gram-negative bacilli.
Membrane-bound kinases affecting
transcription of arn complex through
intermediate PmrD are shown.
Circled P denotes phosphorylation;
circled minus sign denotes negative
regulation of transcription; encircled
plus sign denotes positive regulation.
The two most common sites of mu-
tation are shown in bold.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 899–905
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with caution, as susceptibility testing of polymyxins is techni-
cally challenging and method dependent.
Finally, speciﬁc investigations of occurrence of colistin resis-
tance in genotypically conﬁrmed carbapenemase-producing
K. pneumoniae have revealed colistin resistance in 23% of
K. pneumoniae carbapenemase (KPC)producers fromanationwide
Italian study (n = 204) [9], 25% of metallo-β-lactamase producers
from Madrid (n = 63) and 14% of KPC producers from Madrid
(n = 14) [10]. These studies corroborate some of the ﬁndings in
the EARS-Net report and suggest that the high resistance levels
in carbapenem-resistant K. pneumoniae is probably a true obser-
vation which cannot be fully explained by methodology issues.TemocillinTemocillin is the 6-α-methoxy derivative of ticarcillin, with high
afﬁnity to penicillin-binding protein 2 [11]. The α-methoxy group
blocks the entry of a water molecule into the β-lactamase active
site cavity, preventing activation of the serine and the chemical
events leading to hydrolysis. The negative consequence of this
modiﬁcation is that temocillin’s binding to many penicillin-binding
proteins is also impaired, explaining its lack of activity against
Gram-positive bacteria aswell as nonfermenters [12]. Breakpoints
for antimicrobial susceptibility testing are not available from either
European Committee on Antimicrobial Susceptibility Testing
(EUCAST) or the Clinical and Laboratory Standards Institute, but
pharmacokinetic/pharmacodynamic data from the literature sug-
gest that with the current every-12-hour dosing regimen, a sus-
ceptible breakpoint of 8 mg/L would probably be appropriate
[13] and is normally used as a tentative breakpoint.
It has been known for around a decade that temocillin has
high activity against extended-spectrum β-lactamase (ESBL)-
and AmpC-producing Enterobacteriaceae [14–16]. In recent
years, it has become clear that although the activity is high, the
resistance levels are still higher in ESBL and AmpC producers
than in wild-type isolates. A South Korean study of community-
acquired UTI showed that the temocillin resistance was 12.5%
among ESBL- and plasmid-mediated AmpC-producing E. coli,
but only 2.5% in wild-type E. coli [17]. Two Swedish studies of
ESBL-producing E. coli and K. pneumoniae showed that the
overall resistance to temocillin was 17% to 24%, and higher
among isolates producing enzymes belonging to the CTX-M-1
group [18,19]. In both these studies, many of the isolates had
minimum inhibitory concentrations (MICs) one dilution step
above the tentative S breakpoint, and such MIC levels could
potentially be achievable with higher dosing regimens.
Apart from the activities against ESBL- and AmpC-
producing Enterobacteriaceae, temocillin has also beenClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologysuggested as a potential treatment alternative for some car-
bapenemase producers. One study from the United Kingdom
showed that half of all KPC producers were in vitro susceptible
to temocillin, but in the same study all VIM, IMP, NDM and
OXA-48 producers were resistant [20]. Another study from
Belgium demonstrated that very few carbapenemase pro-
ducers were susceptible to temocillin, and that OXA-48
producers were always high-level resistant to the compound
[21]. The latter feature has also been utilized in carbapene-
mase characterization algorithms, as high-level temocillin
resistance serves as a phenotypic OXA-48 marker (EUCAST
guidelines, http://www.eucast.org/ﬁleadmin/src/media/PDFs/
EUCAST_ﬁles/Resistance_mechanisms/EUCAST_detection_of_
resistance_mechanisms_v1.0_20131211.pdf). There is currently
no clinical evidence suggesting that KPC producers are treatable
with temocillin, but still the in vitro ﬁndings are interesting and
could point to a putative effect of temocillin against this group of
carbapenemase producers. Versus MBL and OXA-48 producers,
temocillin appears to have no clinically useful activity.FosfomycinFosfomycin is a low-molecular-weight phosphonic acid derivative
mainly used for the treatment of UTI and is available both for oral
and intravenous use. The mechanism of action is the initial step in
the peptidoglycan synthesis, where the compound binds MurA
[22]. The antimicrobial enters into the active site of MurA and
inhibits the enzyme by covalent binding with a key residue in the
active site, Cys115 [22]. The most common mechanism of resis-
tance is decreased permeability, followed by enzymatic modiﬁca-
tion of fosfomycin by plasmid-encoded glutathione transferases
(mainly fosA), and ﬁnally modiﬁcation of the fosfomycin binding
site Cys115, which is an uncommon mechanism [22].
A German multicentre study of outpatients infected by E. coli
(n = 499) showed that resistance to fosfomycin was observed in
less than 2% of the patients [23]. In the same collection, cef-
podoxime resistance was seen in 8% to 10% of the patients and
ciproﬂoxacin resistance was seen in 32% of male patients and
9% to 25% of female patients (which varied by different age
groups). Another German study of 107 carbapenem-
nonsusceptible Enterobacteriaceae isolates, of which 80 pro-
duced various types of carbapenemases, including KPC, VIM,
NDM and OXA-48, showed that 78% of the strains were
susceptible to fosfomycin according to EUCAST [24]. A
nationwide study from South Korea on community-acquired
infections caused by E. coli showed that 3% of the isolates
were resistant to fosfomycin [17]. Another Chinese study of
UTI isolates of E. coli from 2004 to 2012 showed 6.2% resis-
tance in ESBL producers and 1.6% in wild-type isolates [25].and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 899–905
TABLE 2. Mecillinam susceptibility in Escherichia coli from
female patients in ﬁve European countries
Study France Germany Spain Sweden UK
ECO.SENS 2000 [39] 1.5 2.2 1.0 1.6 2.8
ECO.SENS 2008 [40] — — — 0.5 1.0
LEO 2014 (Matuschek and Kahlmeter,
poster presented at 25th ECCMID,
Copenhagen, 2015)
3 3a 6.5 1.5 4.8
ECCMID, European Congress of Clinical Microbiology and Infectious Diseases.
aIsolates are of mixed origin, not only primary care.
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are evident in areas where the compound has been used
extensively. For instance, data from Granada, Spain, showed
that susceptibility levels had dropped signiﬁcantly between 2006
and 2012, both in strains from community-acquired and
hospital-acquired UTI [26]. Another word of caution is the
emergence of plasmid-mediated fosfomycin resistance, which
could potentially have a greater propensity to spread than
chromosomal resistance mechanisms. Data from Hong Kong
Hong Kong from 2008 to 2010 point to the emergence of fosA
both in livestock and other animals. A collection of 1693 E. coli
from 2106 animals (210 beef cattle, 214 pigs, 460 broiler
chickens, 398 stray cats, 368 stray dogs, 456 wild rodents) was
investigated. Among the 101 fosfomycin-resistant strains, 97
were fosA3 positive, and 93 of these were blaCTX-M producing
[27]. The emerging association between fosA and blaCTX-M has
not been explored in European strain collections, but it is
concerning and should be monitored closely.MecillinamMecillinam, or 6β-amidinopenicillanic acid, is a penicillin deriv-
ative which has been used extensively in the Scandinavian
countries for UTI treatment since the early 1980s [28]. TheClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectantimicrobial has a high concentration in the urine and has been
found to have low impact on the intestinal microbiota [29,30].
The mode of action is primarily inhibition of penicillin-binding
protein 2 (PBP2) [31]. PBP2 is responsible for elongation of
rod-shaped cells, and PBP2 mutants failing to bind mecillinam
will grow as ovoid cells [32]. Mechanisms of mecillinam resis-
tance in clinical isolates are poorly understood, although several
attempts have been made to elucidate this issue. A majority of
ESBL-producing Enterobacteriaceae are susceptible to mecilli-
nam [18,19], although clinical data on treatment efﬁcacy are
relatively scarce [33,34]. One study found high rates of treat-
ment failure in UTI caused by ESBL-producing E. coli [35], but it
should be noted that the study did not only include uncom-
plicated UTI, which is the indication of the drug. Treatment
failure related to off-label use is always difﬁcult to ascertain.
Moreover, while mecillinam have been reported resistant to
some oxacillinases [36], recent data suggest that NDM and IMP
producers are frequently in vitro susceptible to mecillinam,
while KPC and VIM producers are resistant [37]. Unpublished
data also suggest that mecillinam is highly in vitro active against
OXA-48 producers (C. G. Giske, 2015, unpublished data).
Recently, a study showed that mutation in cysB preventing
production of cysteine is the major mechanism of mecillinam
resistance in clinical isolates. The mechanism seems to be that
reduced cysteine productions leads to an increased cellular
concentration of the molecule ppGpp, and these elevated
cellular levels render the target of mecillinam, PBP2, nones-
sential [38].
Systematic surveillance data for mecillinam are largely lack-
ing, but data from the ECO.SENS studies provide some insight
in susceptibility levels in outpatient UTIs caused by E. coli in
Europe (Table 2) [39,40]. Recent data are also available from
ﬁve European countries and indicate somewhat increasing
resistance levels to mecillinam compared with recent years,
although still at a very low level (Matuschek and Kahlmeter,FIG. 2. E. coli resistance levels to
mecillinam and nitrofurantoin in a
Swedish university hospital,
2011–2013. Range of tested E. coli per
year: 22 142 to 23 951. Number of
ESBL-producing E. coli: range 637–830.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 899–905
FIG. 3. Mechanism of action for nitro-
furantoin and genes affected by mutations in
resistant isolates.
CMI Giske Resistance trends in old antibiotics 903poster presented at 25th European Congress of Clinical
Microbiology and Infectious Diseases (ECCMID), Copenhagen,
2015). Data from a large university laboratory in Sweden are
shown in Fig. 2, along with susceptibility data for nitrofurantoin.
The data show that overall resistance in E. coli for the years
2011 to 2013 (based on >20 000 tested isolates per year) is
between 4% and 5%, whereas resistance levels in ESBL-
producing E. coli range between 5% and 7% (C. G. Giske,
2015, unpublished data from Karolinska University Hospital,
Stockholm, Sweden). These resistance levels are observed in a
clinical setting where 87% of the patients receive either
mecillinam or nitrofurantoin for uncomplicated UTI [41]. The
ﬁnding of high susceptibility levels for ESBL-producing strains is
corroborated by similar numbers found in cefpodoxime-
resistant E. coli in the United Kingdom. In a study by Woot-
ton et al. [42], only 6.2% of cefpodoxime-resistant E. coli were
resistant to mecillinam.NitrofurantoinTABLE 3. Nitrofurantoin susceptibility in Escherichia coli from
female patients in ﬁve European countries
Study France Germany Spain Sweden UK
ECO.SENS 2000 [39] 1.0 0.7 4.2 0 0
ECO.SENS 2008 [40] — — — 0 0
LEO 2014 (Matuschek and Kahlmeter,
poster presented at 25th ECCMID,
Copenhagen, 2015)
0 2.3a 0 1.5 5.6
ECCMID, European Congress of Clinical Microbiology and Infectious Diseases.
aIsolates are of mixed origin, not only primary care.Nitrofurans are compounds containing one or more nitro
groups on a nitroaromatic or nitroheterocyclic background, and
the most clinically important representative of this drug class is
nitrofurantoin [43]. The antimicrobial is taken orally and results
in high urinary concentrations, for which reason it is suitable as
a lower UTI agent [44]. A recent metagenomic analysis of faecal
samples from patients with UTI treated with nitrofurantoin
demonstrated a very low impact of treatment on the faecal
microbiota [45]. The mode of action is reduction of nitrofuransClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologyto toxic intermediate compounds that can interfere with en-
zymes in DNA, RNA and protein synthesis (Fig. 3) [46,47]. The
mechanism of resistance seems to be mainly mutations in nfsA or
nfsB, both of which are encoding oxygen-insensitive nitro-
reductases [43]. The lack of reduction of the substance prevents
the formation of toxic intermediate compounds [46]. Recently,
deletion in ribE, encoding lumazine synthase needed for riboﬂavin
biosynthesis, has also been shown to increase MIC levels in
laboratory mutants, although these mutations have so far not
been described in clinical isolates [46].
Similar to mecillinam, nitrofurantoin data from European
outpatients infected by E. coli have generally shown very low
resistance levels (Table 3) [39,40] (Matuschek and Kahlmeter,
poster presented at 25th ECCMID, Copenhagen, 2015). Data
from a large university hospital in Sweden where use of the
drug is very high indicate resistance levels just above 1% in
clinical isolates of E. coli, whereas resistance in ESBL-producing
E. coli is somewhat higher, at approximately 4% (Fig. 2). A likely
explanation for the low occurrence of resistance despite high
usage could be the low ﬁtness of nfsA/nfsB mutants [43].and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 899–905
904 Clinical Microbiology and Infection, Volume 21 Number 10, October 2015 CMIConcluding remarksOf the above-mentioned agents, it is likely that more surveillance
data will be available in the future for colistin, as many countries
already report data to EARS-Net. Temocillin data may also
become more available if the drug is licensed in more European
countries, which is already an ongoing process. Regarding agents
for treatment of UTI, it is less likely that public surveillance data
will become available in the near future, but surveillance beyond
blood cultures should still be a priority for the future.Transparency declarationThe author reports no conﬂicts of interest relevant to this
article.AcknowledgementsThanks to E. Matuschek and G. Kahlmeter for providing 2014
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